SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS — Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, today reported financial results for the third quarter 2026 ended September 30, 2026, and…

ALCLS
SquawkNews Desk

Related stories

More Than 10,000 Flights Delayed or Canceled Saturday Airlines are working to restore normal schedules. M impact | EQUITY | Nov 14, 2026, 07:34 PM UTC Flight Cancellations Mount at DFW and Love Field After FAA Ground Stop Cancellations mounted Saturday morning at DFW International Airport and Dallas Love Field after an FAA ground stop was lifted. M impact | EQUITY | Nov 14, 2026, 07:03 PM UTC Thousands of US Flights Canceled and Delayed as Air Travel System Recovers Thousands of US flights were canceled or delayed as the air travel system slowly recovered from a shutdown. M impact | EQUITY | Nov 14, 2026, 06:37 PM UTC Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC Lilly Phase 2 Data Show Eloratzp Weight Loss of Up to 54.1 Pounds Phase 2 data showed average weight loss of up to 54.1 pounds (23.3%) at 48 weeks in adults with obesity and type 2 diabetes. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC Novo Nordisk CagriSema Reduced Waist Circumference by 17.2–17.5 cm Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC